F-1/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

F-1/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

F-3 - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

20-F/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

S-8 - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

20-F - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025. The event, held at the Lotte New York Palace Hotel in New York City and virtually, features more than 550 corporate presentations from leading growth companies across healthcare, technology, and finance. Dr. Neil Maresky, CEO of Psyence BioMed, will provide an overview of the Company's business strategy and pipeline.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ:PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psychedelic therapies for people living with serious mental health challenges. Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. These developments reflect not only a shift in our momentum but also a broader evolution of the company – one I'm excited to share with you. Clinical Progress & Trial Expansion Psyence

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLabs and continued that investment in 2025. This achievement reflects the impact of Psyence BioMed's ongoing investment and collaboration, which continues to support PsyLabs' development of

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the "Offering") of common shares in the capital of the Company (the "Common Shares"). Pursuant to the Offering, the Company has raised gross proceeds of C$600,000 split into two tranches. Tranche 1 closed today, and the Company has issued an aggregate of 4,760,000 Common Shares at a price of C$0.10 per Common Share for gross proceeds of C$476,000. Tranche 2 is anticipated to close on or

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce an offering of a non-brokered private placement (the "Offering") of up to 6,000,000 common shares of the Company (the "Common Shares") at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder's fees or commissions will be payable in connection with the Offering. The Company intends to use the net proceeds of the Offering to evaluate and pursue potential strategic transactions, including the identification, due diligence,

Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein joins Dr. Albert Garcia-Romeu (Chair

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants hav

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrant in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant in a private placement. The series A common warrants and short-term series B common warra

NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements. As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders' equity requirement. Addi

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the "Meeting"). Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions (the "Resolutions" and each a "Resolution") were submitted to and approved by the Company's shareholder

Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings

SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)